復星醫藥(600196.SH):mRNA新冠疫苗於中國境內尚處於II期臨牀試驗階段
格隆匯 4 月 30日丨復星醫藥(600196.SH)公佈,公司A股股票於2021年4月28日、4月29日、4月30日連續三個交易日收盤價格漲幅偏離值累計超過20%。
截至2021年4月30日,公司控股子公司上海復星醫藥產業發展有限公司獲BioNTech許可的用於預防新型冠狀病毒肺炎的mRNA疫苗BNT162b2 (“mRNA新冠疫苗”或“該疫苗”)已分別被使用於中國香港、中國澳門的政府接種計劃。截至2021年4月30日,該疫苗於中國境內尚處於II期臨牀試驗階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.